id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2020-N-0026-0036,FDA,FDA-2020-N-0026,Issuance of Priority Review Voucher; Rare Pediatric Disease Product; Gomekli (mirdametinib),Notice,Announcement,2025-03-13T04:00:00Z,2025,3,2025-03-13T04:00:00Z,,2025-03-13T12:56:52Z,2025-04021,0,0,09000064869e6ed4
FDA-2020-N-0026-0035,FDA,FDA-2020-N-0026,Issuance of Priority Review Voucher; Rare Pediatric Disease Product; ALHEMO (concizumab-mtci),Notice,General Notice,2025-01-15T05:00:00Z,2025,1,,,2025-01-15T14:35:52Z,2025-00750,0,0,09000064868c0464
FDA-2020-N-0026-0034,FDA,FDA-2020-N-0026,Issuance of Priority Review Voucher; Rare Pediatric Disease Product; CRENESSITY (crinecerfont),Notice,Announcement,2025-01-10T05:00:00Z,2025,1,2025-01-10T05:00:00Z,,2025-01-10T13:53:44Z,2025-00340,0,0,09000064868ade79